Highland Capital Management (Texas)’s Pacira BioSciences PCRX Stock Holding History

Highland Capital Management (Texas)’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$707K	Hold	16,250	–	–	0.04%	233
2019 Q1	$618K	Buy	16,250 +7,500	+86%	+$293K	0.04%	234
2018 Q4	$376K	Hold	8,750	–	–	0.03%	215
2018 Q3	$430K	Buy	+8,750	New	+$378K	0.02%	242
2017 Q3	–	Sell	-67,000	Closed	-$3.2M	–	335
2017 Q2	$3.2M	Sell	67,000 -29,000	-30%	-$1.35M	0.14%	117
2017 Q1	$4.38M	Buy	96,000 +25,321	+36%	+$1.09M	0.22%	104
2016 Q4	$2.28M	Sell	70,679 -57,700	-45%	-$1.93M	0.11%	136
2016 Q3	$4.39M	Buy	128,379 +29,179	+29%	+$1.14M	0.13%	136
2016 Q2	$3.35M	Buy	99,200 +26,502	+36%	+$1.3M	0.14%	137
2016 Q1	$3.85M	Buy	+72,698	New	+$4.25M	0.17%	136
2015 Q4	–	Sell	-242,455	Closed	-$9.96M	–	279
2015 Q3	$9.96M	Buy	+242,455	New	+$14.9M	0.29%	98
2015 Q1	–	Sell	-29,573	Closed	-$2.62M	–	247
2014 Q4	$2.62M	Sell	29,573 -6,623	-18%	-$626K	0.09%	125
2014 Q3	$3.51M	Buy	+36,196	New	+$3.52M	0.13%	127

Other funds holding PCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Highland Capital Management (Texas)'s PCRX Position: Q2 2019 in Review

Highland Capital Management (Texas) held its Pacira BioSciences (PCRX) position steady in Q2 2019 at 16,250 shares worth $707K. The position accounts for 0.04% of the portfolio, ranked #233.

Highland Capital Management (Texas) first reported a position in PCRX in Q3 2014 and has held it in 13 quarters since. The position peaked at $9.96M in Q3 2015. 218 funds tracked by Wall St. Rank hold PCRX as of Q2 2019.

Highland Capital Management (Texas) held 16,250 shares of Pacira BioSciences worth $707K as of Q2 2019.
Highland Capital Management (Texas) left its Pacira BioSciences share count unchanged in Q2 2019.
Pacira BioSciences made up 0.04% of Highland Capital Management (Texas)'s portfolio in Q2 2019, its #233 holding.
Highland Capital Management (Texas) first reported a position in Pacira BioSciences in Q3 2014 and has held it in 13 quarters since.
Highland Capital Management (Texas)'s Pacira BioSciences position peaked at $9.96M in Q3 2015.
218 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2019.

Based on Highland Capital Management (Texas)'s 13F filing for Q2 2019, filed 14 Aug 2019.